Longer-term virologic outcomes on tenofovir-lamivudine-dolutegravir in second-line ART
Among adults switching to TLD with detectable HIV-1 RNA and substantial tenofovir and lamivudine resistance, a high proportion maintained virologic suppression up to 158 weeks. Emergent dolutegravir resistance occurred in ~1% of participants after 2-3 years on second-line TLD.
Authors
- Kayla Delaney (ORCID: https://orcid.org/0000-0001-5845-5778)
- Graeme Meintjes (ORCID: https://orcid.org/0000-0003-1196-4414)
- Gert Uves van Zyl (ORCID: https://orcid.org/0000-0003-3021-5101)
- Gary Maartens (ORCID: https://orcid.org/0000-0003-3080-6606)
- Zaayid Omar (ORCID: https://orcid.org/0009-0001-0844-535X)
- Claire Keene (ORCID: https://orcid.org/0000-0002-0875-5884)
- Jennifer K. van Heerden (ORCID: https://orcid.org/0000-0003-0813-7645)
- Rene T. Goliath (ORCID: https://orcid.org/0000-0001-9818-4634)
- Rulan Griesel (ORCID: https://orcid.org/0000-0003-3633-2878)
- Ying Zhao (ORCID: https://orcid.org/0000-0001-7872-0954)
Institutions
- University of Cape Town (ZA)
- Queen Mary University of London (GB)
- Stellenbosch University (ZA)
- Groote Schuur Hospital (ZA)
- Tygerberg Hospital (ZA)
- University of Oxford (GB)
- Médecins Sans Frontières (ZA)
- Wellcome Centre for Infectious Diseases Research in Africa (ZA)
- Science Oxford (GB)
Publication Details
- Journal
- Southern African Journal of HIV Medicine
- Published
- 2025-04-26
- DOI
- https://doi.org/10.4102/sajhivmed.v26i1.1677
- Citations
- 1
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.40